Helicobacter pylori Infection and Development of Gastric Cancer in Korea

Kim, Nayoung; Park, Ran Young; Cho, Sung-Il; Lim, Seon Hee; Lee, Kye Heui; Lee, Woo Seung; Kang, Hyung Min; Lee, Hye Seung; Jung, Hyun Chae; Song, In Sung

doi:10.1097/mcg.0b013e318046eac3

Cited by 109 publications

(84 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In present study, we directly compared the occurrence of GC and the results suggested that patients with IM or DYS may not benefit from the H. pylori treatment on the risk of GC. Similar results indicating that the baseline of IM was a prior risk factor of GC development after eradication can be obtained in other studies [22][23][24].In the aspect of primary-prevention, Mera et al [8] prescribed eradication therapy to participants allocated in placebo group and prolong the follow up duration from 6 to 12 years, and all 9 GC patients had a baseline diagnosis of IM or DYS. A large population-based study with 4,121 participants showed the 5-year average incidence of GC decreased from 40.3 to 30.4 per 100 000 person-yearsafter eradication treatment.…”

Section: Discussionsupporting

confidence: 69%

Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia: evidence from a meta-analysis

et al. 2015

View full text Add to dashboard Cite

Background The effect of Helicobacter pylori (H. pylori) eradication on gastric cancer (GC) prevention is controversial. Intestinal metaplasia (IM) seems to be a ''point of no return'' in the precancerous cascade. We performed a meta-analysis of randomized controlled trials (RCTs) to illustrate this issue. Materials and Methods The MEDLINE, EMBASE, Cochrane Library were searched for relevant RCTs that were published in any language up to March 2014. By dividing participants into subgroups based on their baseline diagnoses as group \IM (normal, non-atrophic gastritis, atrophic gastritis) and group CIM(intestinal metaplasia, dysplasia), the relative risk (RR) of GC in each study compared treatment group with control group were pooled using Mantel-Haenszel fixed-effect model and publication bias analyses were performed.Results Ten studies from eight RCTs were included in this analysis, for a total of 7,955 participants. H. pylori treatment compared with control significantly reduced the risk of GC, with a pooled RR of 0.64 (95 % CI, 0.48-0.85). Subgroup analysis for patients with non-atrophic gastritis, atrophic gastritis (\IM) yielded a similar results (RR = 0.25, 95 % CI, 0.08-0.81). But this difference was not observed in patients with intestinal metaplasia, dysplasia (CIM) (RR = 0.88; 95 % CI, 0.59-1.31). Conclusions Our results suggested that patients with Intestinal metaplasia or dysplasia could not benefit from the H. pylori treatment on the risk of GC.

show abstract

Section: Discussionsupporting

confidence: 69%

Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia: evidence from a meta-analysis

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Another systematic review also concluded that there is sufficient clinical evidence that H. pylori eradication has a role in the prevention of gastric cancer in patients with chronic non-atrophic gastritis and with atrophic gastritis [226]. Indeed, a large prospective study (mean follow-up of 9.4 years) also suggested that H. pylori eradication before the development of intestinal metaplasia is probably more effective in reducing gastric cancer incidence [235].…”

Section: Surveillancementioning

confidence: 96%

Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED)

et al. 2011

View full text Add to dashboard Cite

Atrophic gastritis, intestinal metaplasia, and epithelial dysplasia of the stomach are common and are associated with an increased risk for gastric cancer. In the absence of guidelines, there is wide disparity in the management of patients with these premalignant conditions. The European Society of Gastrointestinal Endoscopy, the European Helicobacter Study Group, the European Society of Pathology, and the Sociedade Portuguesa de Endoscopia Digestiva have therefore combined efforts to develop evidence-based guidelines on the management of patients with precancerous conditions and lesions of the stomach. A multidisciplinary group of 63 experts from 24 countries developed these recommendations by means of repeat online voting and a meeting in June 2011 in Porto, Portugal. The recommendations emphasize the increased cancer risk in patients with gastric atrophy and metaplasia and the need for adequate staging in the case of high-grade dysplasia, and they focus on treatment and surveillance indications and methods.

show abstract

“…The patients with H. pylori infection and IM had more than 6.4-fold increased risk of gastric cancer than the subjects of infected with H. pylori infection but without IM [ 3 ]. In a cohort study of 2,224 subjects conducted in South Korea, the group with IM had 10.9-fold increased risk of gastric cancer [ 19 ]. H. pylori infection triggers a multistep progression from chronic gastritis, gastric atrophy, IM, and fi nally into gastric cancer [ 29 ].…”

Section: Atrophic Gastritis and Intestinal Metaplasia As Precursor Lementioning

confidence: 94%

Atrophic Gastritis and Intestinal Metaplasia

Kim

Park

2016

Helicobacter Pylori

Self Cite

View full text Add to dashboard Cite

Helicobacter pylori ( H. pylori ) infection causes atrophic gastritis (AG) and intestinal metaplasia (IM), which are known as the main precursor lesions of gastric cancer. The prevalence of AG and IM varies depending on countries, even it represents diverse results in the same nation. Usually AG is antecedent of IM, but the risk factors of AG and IM are not always the same. Furthermore, the management strategy of AG and IM has not been established, yet. However, eradication of H. pylori is very important to prevent the progression of AG and IM to gastric cancer. Therefore, early diagnosis of AG and IM is very important, especially in high incidence area of gastric cancer. However, as the endoscopic, histological, and serological diagnostic tool had a limitation, a multifactorial assessment is needed to ameliorate the diagnostic accuracy of AG and IM.

show abstract

Helicobacter pylori Infection and Development of Gastric Cancer in Korea

Cited by 109 publications

References 22 publications

Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia: evidence from a meta-analysis

Helicobacter pylori eradication cannot reduce the risk of gastric cancer in patients with intestinal metaplasia and dysplasia: evidence from a meta-analysis

Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED)

Atrophic Gastritis and Intestinal Metaplasia

Contact Info

Product

Resources

About